Malaysia MDA Expands Recognition Framework: Singapore HSA And Thailand FDA Added To Approved Competent Authorities (2025 Update)

Malaysia’s Medical Device Authority (MDA) has taken another major step toward regulatory reliance, harmonization, and streamlined medical device approvals across ASEAN markets.

On October 15, 2025, the MDA issued the Second Revised Circular Letter No. 2 Year 2025, together with the updated guidance document MDA/GD/0068 (Second Edition, September 2025).

The most significant development:

• Singapore Health Sciences Authority (HSA) 
• Thailand Food and Drug Administration (Thai FDA) 

have now been officially added as recognized competent authorities under Malaysia’s Conformity Assessment by Verification (CAV) framework.

This expansion substantially strengthens Malaysia’s regulatory reliance ecosystem and creates new opportunities for faster, more efficient medical device market access within ASEAN.

At Maven Regulatory Solutions, we help global medical device manufacturers navigate Malaysia MDA requirements, ASEAN regulatory harmonization, CAV submissions, MeDC@St registration, and regional market expansion strategies.

What Is Malaysia’s CAV Framework?

The Conformity Assessment by Verification (CAV) pathway allows medical devices already approved by recognized international regulatory authorities or notified bodies to undergo an expedited verification-based assessment process in Malaysia.

The framework aims to:

• Reduce duplication in regulatory reviews 
• Accelerate medical device approvals 
• Improve regulatory efficiency 
• Support reliance-based evaluations 
• Enhance ASEAN harmonization 
• Facilitate faster patient access to medical technologies 

The CAV route is particularly beneficial for manufacturers with approvals in mature regulatory jurisdictions.

Newly Recognized Authorities Under Malaysia MDA 

Under the revised MDA/GD/0068, Malaysia now recognizes the following authorities and notified bodies for verification assessments.

Approved Competent Authorities and Notified Bodies

• EU Notified Bodies 
• Japan MHLW 
• Australia TGA 
• Health Canada 
• U.S. FDA 
• U.K. MHRA 
• Singapore HSA (new) 
• Thailand FDA (new) 

The addition of Singapore and Thailand marks a major advancement toward ASEAN regulatory convergence and reliance-based market access.

Why The 2025 Recognition Expansion Matters

The inclusion of Singapore HSA and Thailand FDA significantly expands strategic regulatory opportunities for medical device manufacturers.

Key Benefits Include

• Faster market entry into Malaysia 
• Reduced technical review duplication 
• More predictable approval timelines 
• Stronger ASEAN harmonization 
• Simplified reliance pathways 
• Improved regulatory efficiency 
• Better alignment with international approvals 

Manufacturers already operating in Singapore or Thailand can now leverage existing approvals to support Malaysian registration submissions.

Revised Guidance Document MDA/GD/0070 (Second Edition, October 2025)

Alongside MDA/GD/0068, Malaysia MDA also released the revised:

MDA/GD/0070 – Establishment Guide to Medical Device Registration Submission in MeDC@St Through Conformity Assessment by Verification Process

The updated guidance introduces several important procedural and documentation changes.

1. Expanded Inclusion of Singapore HSA And Thai FDA

Relevant sections throughout the guidance document now formally recognize:

• Singapore HSA approvals 
• Thailand FDA approvals 

within applicable verification submission pathways.

This ensures greater consistency in reliance-based evaluations.

2. Updated Annex 4 Requirements

Annex 4 has been revised to include:

• Submission pathways for Class B, C, and D devices 
• Recognition mechanisms for Singapore and Thailand approvals 
• Clarified verification assessment expectations 
• Updated supporting documentation requirements 

These changes improve submission predictability for manufacturers and Authorized Representatives (ARs).

3. Clarified MeDC@St Submission Expectations

The revised guidance also provides:

• Better defined documentation requirements 
• Improved submission standardization 
• Enhanced dossier consistency expectations 
• Clearer evaluation pathways under CAV 

This should help reduce administrative inconsistencies during device registration.

Malaysia’s Growing Regulatory Reliance Strategy In 2025

The 2025 updates reflect Malaysia MDA’s broader strategy toward international collaboration, reliance programs, and regulatory modernization.

Major Regulatory Milestones In 2025

January 2025

Malaysia MDA announced participation in joint medical device assessments with China’s NMPA.

July 30 – September 30, 2025

Malaysia completed a two-month pilot implementation of the:

• IVD Regulatory Reliance Program 

focused on improving efficiency for in vitro diagnostic device evaluations.

September 1, 2025 – February 28, 2026

Malaysia launched the:

• Second Malaysia–Singapore Regulatory Reliance Program 

further strengthening bilateral regulatory cooperation between the two countries.

What This Means for Medical Device Manufacturers

The revised recognition framework creates several important operational advantages.

1. Faster Registration Pathways

Manufacturers with prior approvals from recognized authorities may benefit from significantly shorter review timelines.

2. Reduced Technical Review Duplication

Existing assessments performed by trusted authorities can now support Malaysian evaluations under the verification route.

3. Greater Regulatory Predictability

Harmonized expectations improve submission planning and regulatory forecasting.

4. Expanded ASEAN Market Opportunities

Companies operating in Singapore and Thailand now have improved leverage for broader ASEAN expansion strategies.

Technical Implications for Medical Device Establishments

Manufacturers, importers, and Authorized Representatives should prepare for several practical compliance implications.

1. Updated Documentation Requirements

Submission packages should align with revised requirements under:

• MDA/GD/0068 
• MDA/GD/0070 

including updated reliance documentation expectations.

2. Harmonized ASEAN Submission Structures

Organizations should align technical documentation with:

• ASEAN Common Submission Dossier Template (CSDT) 
• Singapore HSA documentation formats 
• Thai FDA dossier structures 
• EU MDR/IVDR documentation, where applicable 

3. Impact On Class B, C, And D Devices

Class C and D devices may particularly benefit from reduced duplication in technical evaluations under reliance pathways.

4. MeDC@St Portal Adjustments

Manufacturers should expect ongoing updates to the MeDC@St portal to support:

• New recognized authorities 
• Updated verification workflows 
• Additional submission fields 
• Revised document mapping structures 

Broader ASEAN Regulatory Significance

Malaysia’s expanded recognition framework reflects ASEAN’s broader movement toward:

• Regulatory reliance 
• Mutual recognition approaches 
• Harmonized documentation standards 
• Collaborative assessment models 
• Faster regional approvals 
• Improved regulatory efficiency 

The inclusion of Singapore and Thailand supports stronger alignment with the:

• ASEAN Medical Device Directive (AMDD) 

and reinforces ASEAN’s long-term regulatory convergence goals.

Impact On Global Medical Device Manufacturers

Organizations with strong regional regulatory strategies will be better positioned to leverage these new pathways efficiently.

Emerging Trends in ASEAN Medical Device Regulation

The latest Malaysia MDA updates reflect several broader regional trends.

Emerging Regulatory Trends Include

• Increased regulatory reliance models 
• Expansion of collaborative assessments 
• Stronger ASEAN harmonization efforts 
• Greater use of international approvals 
• More digitalized submission systems 
• Enhanced lifecycle compliance oversight 
• Improved cross-border regulatory cooperation 

ASEAN’s regulatory environment is becoming increasingly interconnected and efficiency focused.

Recommended Actions for Manufacturers

1. Review Existing ASEAN Approvals

Evaluate whether existing Singapore HSA or Thai FDA approvals may support Malaysian submissions.

2. Update Regulatory Submission Strategies

Align market entry planning with the revised CAV recognition framework.

3. Harmonize Technical Documentation

Ensure dossiers support multiple ASEAN jurisdictions efficiently.

4. Monitor MDA Guidance Updates Continuously

Ongoing regulatory intelligence monitoring is essential as Malaysia continues refining reliance pathways.

5. Prepare For MeDC@St Workflow Changes

Internal regulatory teams should anticipate evolving portal and submission requirements.

Quick Facts

• Malaysia MDA expanded its recognition framework in October 2025  
• Singapore HSA and Thailand FDA are now recognized authorities under CAV 
• The update supports ASEAN regulatory harmonization 
• Revised guidance documents include MDA/GD/0068 and MDA/GD/0070 
• Manufacturers may benefit from faster Malaysian market access 
• Class B, C, and D devices are included in updated verification pathways 
• Malaysia continues strengthening international reliance collaborations 
• MeDC@St submission workflows are evolving alongside the updates  

Why This Matters

Malaysia’s expanded recognition framework represents a major advancement in ASEAN medical device regulatory reliance.

Organizations that successfully leverage these pathways may benefit from:

• Faster device approvals 
• Reduced regulatory duplication 
• Lower submission complexity 
• Improved commercialization timelines 
• Better ASEAN market integration 
• Enhanced regulatory predictability 

Manufacturers that fail to adapt may face:

• Longer review timelines 
• Increased administrative burdens 
• Delayed market access 
• Higher compliance costs 

Strategic preparation and harmonized documentation will be essential for maximizing these new opportunities.

How Maven Regulatory Solutions Supports Malaysia MDA Compliance

Our Services

• Malaysia MDA device registration support 
• MeDC@St submission management 
• CAV strategy and verification support 
• ASEAN CSDT dossier preparation 
• Regulatory gap assessments 
• ASEAN market expansion planning 
• Technical documentation harmonization 
• Regulatory intelligence monitoring 
• Authorized Representative coordination 
• Quality system alignment support 

Why Choose Maven

• Strong expertise in ASEAN medical device regulations 
• Practical experience with MDA registration pathways 
• Deep understanding of reliance-based frameworks 
• End-to-end submission management support 
• Up-to-date regional regulatory intelligence 
• Strategic guidance for multinational manufacturers 
• Efficient ASEAN commercialization planning 

Learn more at Maven Regulatory Solutions.

Need Support with Malaysia MDA Device Registration?

Maven Regulatory Solutions helps global medical device manufacturers navigate Malaysia’s evolving regulatory framework with confidence.

We Help You With

• CAV submission strategy 
• MeDC@St registration support 
• ASEAN CSDT dossier preparation 
• Regulatory reliance planning 
• Technical documentation alignment 
• ASEAN market access strategy 
• MDA regulatory intelligence monitoring 
• Cross-border compliance coordination 

Partner With Maven Regulatory Solutions To:

• Accelerate Malaysian device approvals
• Reduce regulatory duplication
• Strengthening ASEAN compliance readiness
• Improve submission efficiency
• Streamline market expansion
• Maintain regulatory confidence across ASEAN markets

Contact Maven Regulatory Solutions today to strengthen your ASEAN medical device regulatory strategy.

Conclusion

Malaysia’s 2025 expansion of its recognized competent authority framework marks another major milestone in ASEAN regulatory harmonization and reliance-based medical device regulation.

By officially recognizing Singapore HSA and Thailand FDA under the CAV pathway, Malaysia MDA has created new opportunities for faster, more predictable, and more efficient medical device approvals.

Manufacturers that proactively align technical documentation, strengthen ASEAN regulatory strategies, and maintain flexible compliance systems will be best positioned to capitalize on these evolving reliance pathways successfully.

FAQs

1. What is Malaysia’s CAV framework?

The Conformity Assessment by Verification (CAV) framework allows devices approved by recognized authorities to undergo streamlined verification assessments in Malaysia.

2. Which new authorities were added in 2025?

Singapore HSA and Thailand FDA were added as recognized authorities under Malaysia’s updated framework.

3. Which guidelines were updated?

Malaysia revised MDA/GD/0068 and MDA/GD/0070 in 2025.

4. What is MeDC@St?

MeDC@St is Malaysia’s online medical device registration submission portal.

5. Which device classes are affected?

The updated framework includes Class B, C, and D medical devices.

6. How does the update benefit manufacturers?

Manufacturers may experience faster approvals, reduced technical review duplication, and more predictable registration pathways.

7. How does this support ASEAN harmonization?

The framework promotes regulatory reliance, collaborative assessments, and alignment with the ASEAN Medical Device Directive (AMDD).

8. How can Maven help with Malaysia MDA registration?

Maven supports CAV submissions, MeDC@St registrations, ASEAN CSDT preparation, regulatory intelligence, and regional market expansion strategies.